Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $2.75 billion. The enterprise value is $2.04 billion.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
Earnings Date | Aug 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 170.92 million shares outstanding. The number of shares has increased by 9.76% in one year.
Current Share Class | 170.92M |
Shares Outstanding | 170.92M |
Shares Change (YoY) | +9.76% |
Shares Change (QoQ) | +13.48% |
Owned by Insiders (%) | 0.89% |
Owned by Institutions (%) | 50.16% |
Float | 63.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.81 |
P/TBV Ratio | 3.89 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.16, with a Debt / Equity ratio of 0.00.
Current Ratio | 11.16 |
Quick Ratio | 10.42 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.46% and return on invested capital (ROIC) is -41.32%.
Return on Equity (ROE) | -62.46% |
Return on Assets (ROA) | -37.97% |
Return on Invested Capital (ROIC) | -41.32% |
Return on Capital Employed (ROCE) | -61.93% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.14M |
Employee Count | 362 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $891,000 in taxes.
Income Tax | 891,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.22% in the last 52 weeks. The beta is 0.61, so Immunovant's price volatility has been lower than the market average.
Beta (5Y) | 0.61 |
52-Week Price Change | -38.22% |
50-Day Moving Average | 15.13 |
200-Day Moving Average | 22.13 |
Relative Strength Index (RSI) | 54.80 |
Average Volume (20 Days) | 1,443,956 |
Short Selling Information
The latest short interest is 19.92 million, so 11.65% of the outstanding shares have been sold short.
Short Interest | 19.92M |
Short Previous Month | 21.68M |
Short % of Shares Out | 11.65% |
Short % of Float | 31.49% |
Short Ratio (days to cover) | 15.71 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -438.15M |
Pretax Income | -271.89M |
Net Income | -413.84M |
EBITDA | -437.78M |
EBIT | -438.15M |
Earnings Per Share (EPS) | -$2.73 |
Full Income Statement Balance Sheet
The company has $713.97 million in cash and $98,000 in debt, giving a net cash position of $713.87 million or $4.18 per share.
Cash & Cash Equivalents | 713.97M |
Total Debt | 98,000 |
Net Cash | 713.87M |
Net Cash Per Share | $4.18 |
Equity (Book Value) | 707.45M |
Book Value Per Share | 4.16 |
Working Capital | 698.89M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$375.87 million and capital expenditures -$759,000, giving a free cash flow of -$376.63 million.
Operating Cash Flow | -375.87M |
Capital Expenditures | -759,000 |
Free Cash Flow | -376.63M |
FCF Per Share | -$2.20 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -9.76% |
Shareholder Yield | -9.76% |
Earnings Yield | -15.04% |
FCF Yield | -13.69% |
Dividend Details Analyst Forecast
The average price target for Immunovant is $40.14, which is 149.32% higher than the current price. The consensus rating is "Buy".
Price Target | $40.14 |
Price Target Difference | 149.32% |
Analyst Consensus | Buy |
Analyst Count | 10 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |